①Celltrion applies for European product approval for CT-P47 (Roactemra biosimilar) = Celltrion announced on the 13th that it has applied for European product approval for CT-P47 (Roactemra biosimilar). The indications are △ rheumatoid arthritis △ giant cell arteritis △ systemic type juvenile arthritis △ polyarticular type juvenile arthritis △ cytokine release syndrome △ coronavirus -19 infection.
② Hyundai Pharmaceutical decides to convene a general shareholders meeting = Hyundai Pharmaceuticals announced on the 13th that it will hold a regular shareholder meeting on the 29th. At this shareholder meeting, the appointment of outside director Jeon Byeong-jun, approval of financial statements, and an audit report are scheduled. In addition, the company intends to pay a cash dividend of 35 won per share, which will also be decided at this shareholder meeting.
③Daewoong, change in sales or profit/loss structure of more than 30% (15% for large corporations) = Daewoong announced on the 13th that its sales or profit structure has changed by more than 30% (15% for large corporations). Last year’s sales were KRW 1.8138 trillion, and operating profit was KRW 195.6 billion, a decrease of 5.7% compared to the previous fiscal year. During the same period, net profit increased by 57.2% to 189 billion won. The company said its profitability improved due to the launch and sales growth of its subsidiary’s new innovative drugs (Fexuclu, Enblo), and its net profit structure changed due to Nabota’s global market expansion and global technology exports.
④HLB Life Sciences, sales or profit/loss structure varying by more than 30% (15% for large corporations) = HLB Life Science announced on the 13th that its sales or profit and loss structure has changed by more than 30% (15% for large corporations). Last year’s sales fell 1.74% to KRW 97.9 billion, and operating loss during the same period increased 20.64% to KRW 24.3 billion. However, the net profit for the period turned into a surplus at 4.5 billion won. The company announced that its operating loss had increased due to the coronavirus pandemic, and that its net profit had turned into a surplus due to an increase in valuation gains from financial assets held.
⑤ Kyungnam Pharmaceutical, conversion price adjustment = Kyungnam Pharmaceutical announced on the 13th that it has adjusted the conversion price from 1,609 won to 1,335 won. The reason for the adjustment is the adjustment of the conversion price due to the decline in the market price.
⑥DTNC, conversion price adjustment = DT&C announced on the 13th that it had adjusted the conversion price from 5,540 won to 5,013 won. The reason for the adjustment is the adjustment of the conversion price due to the reduction in the stock price.
⑦Hugel, clarification on rumors or reports (unconfirmed) = Hugel re-announced on the 13th that ‘CBC Group is considering delisting Hugel’ reported by Bloomberg on July 12, 2022. Hugel’s largest shareholder is Aphrodite Acquisition Holdings LLC, and CBC Group is Hugel’s co-largest shareholder along with Dione Limited. The company said that the largest shareholder is reviewing strategic plans in relation to the company’s governance structure, but that no decision has been confirmed at this time, as time is needed to make decisions on important issues taking into account various interests.
⑧Daehan Pharmaceutical decides on cash and in-kind dividends = Daehan Pharmaceutical announced on the 13th that it has decided to pay a cash dividend of 750 earned per share of common stock. The dividend record date is December 31st, and the scheduled date for the general shareholders’ meeting is the 28th of next month.
⑨Gemvax decides to approve a clinical trial plan, etc. = Gemvax announced on the 13th that it has received approval for a US phase 2b clinical trial (IND) for ‘GV1001 (development code name)’ as a treatment for progressive supranuclear palsy. The application date was December 16th last year, and the approval date was the 8th. Clinical trials will be conducted in 30 to 40 hospitals in the United States. The purpose of the clinical trial is to evaluate the safety of GV1001 in patients with progressive supranuclear palsy.
⑩Pharmexin, extend the investigation period to determine if it is subject to a significant review = Phambsin announced on the 13th that it is reviewing whether it is subject to a substantive review for eligibility listing and will decide whether it is eligible by March 6 and provide guidance on whether to continue or lift the trading suspension.
⑪Bio Plus, cash and in-kind dividend decision = Bioplus announced on the 13th that it would pay a cash dividend of 70 won per common stock. The dividend record date is December 31 last year.
⑫GI Innovation, change in sales or profit/loss structure of more than 30% (15% for large corporations) = GI Innovation announced on the 13th that its sales or profit and loss structure has changed by more than 30% (15% for large corporations). Last year’s sales were 5.3 billion won, an increase of 52% compared to 2022, operating loss was 53.6 billion won, and net loss for the period was 54.4 billion won. Operating loss and net loss fell by 21.1% and 31.8%, respectively. The company said that sales increased due to the signing of a technology transfer agreement for the development and commercialization of rights to GI-301, an allergy treatment, in Japan, and that operating profit and loss changed due to an improved operating loss due to a reduction in current research and development costs.
⑬HK InnoN, sales performance (provisional) (fair disclosure) = HK InnoN announced on the 13th that sales in 2023 were KRW 828.9 billion, a decrease of 2.1% from the previous year, operating profit during the same period was KRW 65.9 billion, an increase of 25.5%, and net profit was KRW 47.2 billion , and an Increase of 23.8%.
⑭ Chong Kun Dang Holdings, change in sales or profit/loss structure of more than 30% (15% for large corporations) = Chong Kun Dang Holdings announced on the 13th that its sales or profit structure has changed by more than 30% (15% for large corporations). Last year, consolidated sales amounted to KRW 879.8 billion, a decrease of 3.2% from the previous year, operating profit turned into a surplus of KRW 17 billion, and net profit also turned into a surplus of KRW 49.4 billion. The company said management reform, including a reduction in SG&A expenses, and an increase in equity method profit due to technology exports (CKD-510) from its subsidiary (Chong Kun Dang) played a role.
⑮ Curriculum, change in sales or profit/loss structure of more than 30% (15% for large corporations) = Curacle announced on the 13th that its sales or profit and loss structure has changed by more than 30% (15% for large corporations). Last year’s sales were KRW 10.5 billion, an increase of 193.7% over the previous year, operating loss was KRW 9.8 billion, and net loss for the period was KRW 10.9 billion. Operating loss and net loss decreased by 18.2% and 4.84%, respectively.
⑯ Outsourcing, sales or profit/loss structure varying by more than 30% (15% for large corporations) = NGenBio announced on the 13th that its sales or profit and loss structure has changed by more than 30% (15% for large corporations). Last year’s sales were KRW 4.4 billion, a decrease of 60.5% from the previous year, operating loss was KRW 13.4 billion, and net loss for the period was KRW 13.2 billion. The company said sales and operating profit fell due to a decline in sales of personal genetic tests.
⑰Vaxell Bio signs YBL-007 technology delivery contract = Vaxcell Bio announced on the 13th that it has signed a contract with YBiologics to introduce YBL-007 technology. The content of the contract is the acquisition of licenses for the research, development and commercialization of CAR-T and CAR-NK using the genes and proteins of the YBL-007 sequence.
⑱BC World Pharmaceutical, change in sales or profit / loss structure of more than 30% (15% for large corporations) = BC World Pharmaceutical announced on the 13th that its sales or profit structure has changed by more than 30% (15% for large corporations). Consolidated sales last year were KRW 75.1 billion, an increase of 3.3% over the previous year, operating profit during the same period was KRW 6.4 billion, an increase of 241.9%, and net profit was KRW 2.9 billion, an increase of 4738.6%. The main cause of changes in sales or profit structure is explained as conversion of business profit to surplus due to expansion of domestic market share for new and leading products and improvement in profitability.
#HIT알공 #InnoN #sales #year #KRW #billion.. #Operating #profit #increased #KRW #billion
